Renal Cell Carcinoma (Kidney Cancer) (2026): Types, Symptoms, Stages & Treatment

A kidney cancer diagnosis often starts with a mass found incidentally — on an ultrasound or CT scan done for something completely unrelated — rather than from symptoms that led someone to seek care. That’s actually a meaningful piece of information: it means many renal cell carcinomas are caught while still confined to the kidney, when treatment options are broadest and outcomes are generally most favorable.

This guide walks through what renal cell carcinoma actually is, why it’s really a family of related but distinct cancers rather than one disease, and what the diagnostic and treatment path realistically looks like.

What Is Renal Cell Carcinoma?

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, arising from cells in the kidney’s renal tubules — the tiny structures that filter and process urine within the kidney. RCC accounts for roughly 90% of kidney malignancies and is not one uniform disease but a group of distinct cancer subtypes — most commonly clear cell RCC, followed by papillary and chromophobe RCC — each with different biology, imaging appearance, and treatment response.

Many RCCs are discovered incidentally on imaging done for unrelated reasons, often while still confined to the kidney. Treatment ranges from active surveillance for small, low-risk tumors, through kidney-preserving or kidney-removing surgery for localized disease, to immunotherapy and targeted drug therapy for advanced or metastatic disease — with the specific approach depending heavily on subtype, stage, and grade.

RCC vs. Other Kidney Cancers

“Kidney cancer” is sometimes used loosely, but it’s worth being precise, since these are genuinely different diseases requiring different specialists and treatment approaches:

This article focuses specifically on renal cell carcinoma — if you’ve been told you have a different kidney cancer type, much of this content won’t directly apply to your situation.

Types of Renal Cell Carcinoma

RCC has several subtypes, and identifying the specific type is important because treatment and prognosis can differ.

• Clear cell RCC: The most common subtype, accounting for about 75–85% of cases. It is strongly associated with the VHL/HIF pathway and responds to several targeted therapies.
• Papillary RCC: The second most common subtype, accounting for around 10–15%. Current WHO classification no longer routinely divides it into the older Type 1 and Type 2 categories.
• Chromophobe RCC: Accounts for about 5% of cases and generally has a more favourable, slower-growing course than clear cell RCC.
• Rare subtypes: These include collecting duct carcinoma, renal medullary carcinoma, MiT family translocation RCC, SDH-deficient RCC, and FH-deficient RCC. Some can behave more aggressively and may occur in younger patients.

Why subtype matters: Treatment strategies for non-clear cell RCC can differ from those used for clear cell RCC, particularly in advanced disease. Accurate pathology and, when appropriate, molecular testing help guide treatment selection.

Causes and Risk Factors

The exact cause of most individual RCC cases isn’t identifiable, but several risk factors are well-established through research, including cigarette smoking, obesity, high blood pressure, certain occupational and environmental chemical exposures, and family history. Chronic kidney disease and long-term dialysis are also associated with increased risk in specific contexts.

None of these factors directly causes RCC in any given individual — they describe population-level risk patterns, and many people with RCC have none of these risk factors, while most people with these risk factors never develop kidney cancer.

Hereditary Renal Cell Carcinoma

A minority of RCC cases occur in the context of inherited cancer predisposition syndromes, including:

• Von Hippel-Lindau (VHL) disease — associated particularly with clear cell RCC
• Hereditary papillary renal cell carcinoma — associated with papillary RCC
• Birt-Hogg-Dubé syndrome — associated with chromophobe RCC and hybrid oncocytic tumors
• Hereditary leiomyomatosis and renal cell cancer (HLRCC) — associated with an aggressive form of RCC linked to FH gene alterations
• Tuberous sclerosis — in selected renal tumor contexts

Clues that may warrant genetic counseling and testing include young age at diagnosis, bilateral tumors, multifocal tumors within one kidney, multiple affected relatives, multiple primary tumors of different types, or characteristic findings outside the kidney associated with a specific syndrome.

This applies to a minority of RCC patients — most people diagnosed with RCC, particularly at typical ages, do not have an underlying hereditary syndrome, but if any of these clues apply to your situation, it’s worth raising directly with your oncology team.

Symptoms of RCC

Early RCC frequently causes no symptoms at all — this is precisely why so many cases are found incidentally during imaging done for other reasons. When symptoms do occur, they can include blood in the urine, persistent flank or side pain, a palpable abdominal mass in more advanced cases, unexplained weight loss, fatigue, fever without a clear cause, loss of appetite, and anemia.

The historically described “classic triad” of hematuria (blood in urine), flank pain, and a palpable mass is now understood to be uncommon, and when it does occur together, it’s generally associated with more advanced disease rather than typical presentation. The absence of symptoms does not mean the absence of cancer — this is worth understanding precisely because so many RCCs are asymptomatic until found incidentally.

Is Blood in the Urine a Sign of Kidney Cancer?

Hematuria can occur with RCC, but many far more common conditions — urinary tract infections, kidney stones, and benign prostate conditions among others — also cause blood in urine. Visible or persistent blood in urine warrants medical evaluation regardless of the underlying cause, but it should not be assumed to indicate cancer without proper workup.

Paraneoplastic Syndromes

RCC is somewhat unusual among cancers in its capacity to occasionally cause systemic effects unrelated directly to tumor size or location — called paraneoplastic syndromes.

These can include hypercalcemia (elevated blood calcium), hypertension, polycythemia (elevated red blood cell count), unexplained fever, abnormal liver function tests without liver involvement (Stauffer syndrome), and other systemic effects. These occur in a minority of patients, not most, but their presence is a recognized feature of this specific cancer type worth being aware of.

How RCC Is Diagnosed

The diagnostic pathway typically includes: medical history and physical examination, blood and urine tests, imaging (ultrasound, followed by contrast-enhanced CT or MRI), chest imaging for staging where indicated, kidney biopsy in selected cases, pathology review, staging, risk assessment, and multidisciplinary treatment planning.

Blood and urine tests — including kidney function tests, complete blood count, liver function tests, calcium level, and urinalysis — help assess overall health and treatment readiness, but don’t by themselves diagnose RCC.

Ultrasound can detect kidney masses and help distinguish cystic from solid lesions in some cases, but it generally doesn’t provide the detailed characterization needed for definitive diagnosis and staging.

Contrast-enhanced CT is the imaging workhorse for RCC — used to characterize renal masses, assess tumor size, evaluate local extension, check lymph nodes, and look for distant disease. Kidney function needs to be adequate for contrast administration, which your team will assess. MRI may be preferred when CT contrast isn’t suitable, when detailed assessment of vein involvement is needed (RCC can occasionally grow into the renal vein or even the inferior vena cava), or in selected situations where radiation exposure is a specific concern. Neither is universally superior — the right choice depends on your specific clinical situation.

Kidney Biopsy

Not every renal mass requires biopsy before treatment — this is a genuinely nuanced area of RCC care. Biopsy is particularly useful when imaging findings are uncertain, when distinguishing RCC from a benign lesion matters for treatment decisions, or specifically when considering active surveillance, ablation, or systemic therapy without immediate surgery — situations where knowing the exact subtype before committing to a treatment path is valuable. Biopsy does have real limitations, including sampling error, where the biopsied tissue may not fully represent tumor heterogeneity.

Your urologic oncology team will determine whether biopsy adds meaningful information for your specific situation.

Pathology and RCC Grade

Pathology determines RCC subtype, grade, relevant histologic features, and — increasingly — molecular characteristics that can inform prognosis and treatment selection, particularly for non-clear-cell subtypes.

Grading uses the modern WHO/ISUP grading system (which has largely superseded the older Fuhrman system), primarily applied to clear cell and papillary RCC, ranging from Grade 1 (least aggressive-appearing) to Grade 4 (most aggressive-appearing) based on how the tumor cells’ nuclei appear under the microscope. Higher grade generally correlates with more aggressive biological behavior.

Grade vs. Stage — A Critical Distinction

These describe genuinely different things and are not interchangeable — a tumor can be low-grade but more advanced-stage, or high-grade but early-stage. Both factor into overall treatment planning and prognosis together, not as substitutes for each other.

Kidney Cancer Staging (TNM)

RCC staging uses the AJCC TNM system: T (primary tumor extent), N (regional lymph node involvement), and M (distant metastasis), combined into an overall stage:

Stage I — a tumor generally confined to the kidney and 7 cm or smaller, without lymph node or distant spread.

Stage II — a tumor still confined to the kidney but larger than 7 cm, without lymph node or distant spread.

Generally Stage III — involves either significant local extension (such as growth into the renal vein, perinephric fat, or inferior vena cava below the diaphragm) and/or involvement of regional lymph nodes, without distant metastasis.

Stage IV — generally reflects either very advanced local extension beyond Stage III criteria (such as invasion beyond Gerota’s fascia or into the adrenal gland) and/or the presence of distant metastasis.

Stage IV does not automatically mean end-of-life care or that treatment options have run out. Modern systemic therapies — discussed in detail below — can provide durable disease control for many patients with metastatic RCC, sometimes for years. This is one of the most important points to understand if you or a loved one has received an advanced-stage diagnosis.

Roughly 25-33% of patients present with overt metastatic disease already at diagnosis, according to published data — a meaningful minority, though the majority of patients are diagnosed with disease still confined to or near the kidney.

Metastatic RCC

RCC metastasizes most commonly to the lungs, followed by bone, liver, lymph nodes, adrenal glands, and, less commonly, the brain. Metastatic RCC is managed fundamentally differently from localized disease — systemic therapy, rather than surgery alone, becomes the primary treatment approach, and outcomes vary considerably between patients depending on the number and location of metastatic sites, RCC subtype, and response to treatment.

Not all metastatic RCC patients have the same prognosis — this is genuinely one of the more variable advanced-cancer presentations, discussed further in the prognosis section below.

RCC Treatment Overview

Treatment depends on stage, subtype, grade, tumor size and location, kidney function, age, overall health, surgical fitness, metastatic burden if present, and risk category. The full range of approaches includes active surveillance, partial or radical nephrectomy, ablation, systemic therapy (immunotherapy and/or targeted therapy), radiation for selected metastatic sites, and clinical trials.

Active Surveillance

For selected small renal masses — particularly in older patients, those with significant comorbidities, or tumors with imaging characteristics suggesting lower-risk behavior — active surveillance (monitoring with planned imaging rather than immediate treatment) may be a reasonable option rather than immediate intervention.

This is not “ignoring” the tumor — it’s a structured monitoring approach considering tumor size, growth rate on serial imaging, patient age, life expectancy, kidney function, and overall health, with a clear plan to intervene if the tumor’s behavior changes.

Partial Nephrectomy vs. Radical Nephrectomy

Partial nephrectomy removes the tumor while preserving the remainder of the affected kidney, and is generally preferred for appropriate localized tumors when technically feasible — kidney preservation matters considerably for long-term kidney function, particularly if the other kidney isn’t entirely healthy or if there’s any possibility of future kidney issues.

Radical nephrectomy removes the entire affected kidney and may be appropriate for larger, more centrally located, or more complex tumors where partial removal isn’t technically suitable.

Both can be performed via open, laparoscopic, or robotic-assisted approaches — the right surgical approach depends on tumor characteristics, surgeon expertise, and hospital capability, and robotic surgery is not automatically superior for every case, though it can offer advantages for appropriately selected tumors.

Ablation

Cryoablation and radiofrequency ablation — techniques that destroy tumor tissue using extreme cold or heat rather than surgical removal — may be considered for selected small renal masses, particularly when surgery carries elevated risk due to patient factors. Ablation isn’t suitable for every RCC and is generally reserved for smaller, favorably located tumors in appropriately selected patients.

Immunotherapy and Targeted Therapy for Advanced RCC

Systemic treatment for advanced or metastatic RCC has been genuinely transformed over the past decade by immune checkpoint inhibitors and targeted therapies working together.

Immunotherapy, using immune checkpoint inhibitors, works by helping the immune system recognize and attack cancer cells rather than directly killing tumor cells itself. Current combination approaches for advanced clear cell RCC, per current guideline recommendations, include nivolumab plus ipilimumab, pembrolizumab plus axitinib, pembrolizumab plus lenvatinib, and nivolumab plus cabozantinib — combination regimens pairing immunotherapy with a targeted agent have generally shown better outcomes than either approach alone in appropriate patients.

Targeted therapy acts on specific molecular pathways important in RCC biology, particularly VEGF (vascular endothelial growth factor) signaling, which is closely tied to clear cell RCC’s underlying biology. Common agents include cabozantinib, axitinib, pazopanib, sunitinib, and lenvatinib (VEGF receptor tyrosine kinase inhibitors), and everolimus (an mTOR inhibitor).

Not every patient receives combination therapy — treatment selection is individualized based on RCC subtype, risk category (discussed below), overall health, and treatment goals, and there is no single universally “best” regimen across all patients.

Adjuvant Therapy After Surgery

For selected high-risk clear cell RCC patients after nephrectomy, adjuvant pembrolizumab (immunotherapy given after surgery, aiming to reduce recurrence risk) is a current guideline-supported option based on clinical trial evidence showing improved disease-free survival in appropriately selected high-risk patients. This is not automatically recommended after every nephrectomy — it applies specifically to higher-risk clear cell RCC based on defined criteria, and whether it’s a good match for your specific situation is a discussion to have directly with your medical oncologist. Notably, whether a similar approach benefits high-risk papillary RCC specifically remains an active area of ongoing clinical trial investigation rather than an established practice.

Cytoreductive Nephrectomy

For patients with metastatic RCC at diagnosis, removing the primary kidney tumor (cytoreductive nephrectomy) alongside systemic therapy is not automatically appropriate for everyone — this decision depends heavily on overall health, extent and burden of metastatic disease, and response to initial systemic therapy.

Current practice has moved away from routine upfront cytoreductive nephrectomy for all Stage IV patients toward more selective, individualized decision-making, often considering surgery after initial systemic therapy response has been assessed rather than before.

Radiation Therapy

RCC has historically been considered relatively resistant to conventional radiation as a primary treatment, but modern stereotactic radiation techniques (delivering precisely focused, higher-dose radiation) have a genuine role in selected situations — particularly for brain metastases (using stereotactic radiosurgery), painful bone metastases, or carefully selected oligometastatic disease (a limited number of metastatic sites). Radiation is not the standard primary treatment for most localized RCC, where surgery remains central.

For bone metastases specifically, watch for new severe back pain, weakness, or bowel/bladder dysfunction — these can indicate spinal cord compression, a genuinely urgent situation requiring prompt evaluation rather than routine follow-up scheduling.

Recurrent RCC

RCC can recur after treatment, locally, regionally, or at distant sites. Treatment approaches for recurrence depend on the site and number of lesions, time elapsed since original surgery, RCC subtype, prior therapy received, and whether the recurrence is surgically resectable — options can include further surgery, ablation, radiation, immunotherapy, targeted therapy, or clinical trial participation, following the same general principles as initial treatment but adapted to the specific recurrence pattern.

Prognosis and Survival

Prognosis depends on stage, grade, RCC subtype, tumor biology, overall performance status, metastatic burden if present, and response to treatment. We will not give you one universal RCC survival number — localized clear cell RCC, localized chromophobe RCC (generally more indolent), and metastatic non-clear-cell RCC (generally more challenging to treat with current systemic therapies) represent genuinely different prognostic pictures under the single umbrella term “renal cell carcinoma.”

IMDC Risk Classification for Metastatic RCC

For metastatic RCC specifically, clinicians commonly use the International Metastatic RCC Database Consortium (IMDC) risk model, which incorporates factors including time from diagnosis to systemic treatment, performance status, and specific blood test values (including calcium, hemoglobin, neutrophil count, and platelet count) to classify patients into favorable, intermediate, or poor risk categories.

This risk classification helps guide treatment selection and provides population-level prognostic context — it does not predict an individual patient’s specific outcome, and your oncology team can explain how your specific IMDC risk category relates to your treatment plan.

Follow-Up After Treatment

Surveillance intensity and duration depend on your original stage, grade, treatment received, and recurrence risk. Monitoring typically includes periodic CT or MRI imaging, chest imaging, blood tests including kidney function, and clinical examination — there’s no single universal schedule, and your team will define a follow-up plan specific to your risk profile, generally more frequent in the first few years after treatment and less frequent over time if no recurrence occurs.

Living With One Kidney

Many people live full, healthy lives with a single functioning kidney, whether from radical nephrectomy or born with one kidney. Key considerations include periodic kidney function monitoring, blood pressure control (since hypertension can stress kidney function over time), avoiding unnecessary kidney-stressing substances or medications without medical guidance, and maintaining regular follow-up with a healthcare provider.

RCC Treatment Cost in India

There’s no single universal kidney cancer treatment price, and it genuinely helps to separate this by treatment category, since surgical cost and systemic (drug) therapy cost behave very differently — one is a defined one-time procedure, the other can be an ongoing monthly or per-cycle expense.

RCC Treatment in India for International Patients

India offers relevant infrastructure for kidney cancer care — urologic oncology, robotic surgical capability, interventional radiology for ablation, pathology, and access to current immunotherapy and targeted therapy regimens, generally at costs substantially below equivalent care in the US, UK, or Western Europe. What matters when evaluating a specific center includes:

• Urologic oncology and renal cancer surgery experience specifically, including partial nephrectomy capability (not every urology department routinely offers kidney-sparing surgery for complex tumors)
• Pathology capable of accurate subtype identification, particularly important for non-clear-cell RCC where treatment approach differs meaningfully
• Medical oncology experience with current immunotherapy/targeted therapy combination regimens
• Interventional radiology for ablation where relevant
• A functioning multidisciplinary tumor board

We’re not going to claim India is automatically “the best” option without your specific case being evaluated — what genuinely matters is confirming a center’s renal cancer surgical volume specifically and their approach to kidney preservation, not just general urology or oncology volume.

Choosing a Kidney Cancer Treatment Center

Rather than a superficial “top hospitals” list, look for a center offering urologic oncology, renal cancer surgery specifically, medical oncology, radiology and interventional radiology, pathology with subtype-specific expertise, radiation oncology, nephrology support, robotic/laparoscopic surgical capability where appropriate, and a functioning multidisciplinary tumor board. If a hospital is named to you, verify these capabilities directly rather than relying on marketing claims alone.

International Patient Journey

1. Share CT/MRI and medical reports for initial specialist review
2. Imaging review and diagnosis confirmation, including subtype determination where tissue is already available
3. Stage and grade assessment, along with kidney function evaluation
4. Urologic oncology consultation to determine whether surgery, surveillance, or systemic therapy is the appropriate path
5. Treatment plan and case-specific cost estimate
6. Medical visa assistance
7. Travel and accommodation planning
8. Treatment — surgery, ablation, and/or initiation of systemic therapy per your plan
9. Follow-up imaging and kidney-function monitoring
10. Long-term surveillance and return-home coordination

We coordinate each of these steps but cannot guarantee diagnosis, surgical eligibility, kidney preservation, complete tumor removal, cure, treatment response, exact cost, visa approval, or survival before your case has been medically evaluated.

How Shifam Health Can Help

An RCC diagnosis brings a genuinely wide range of possible paths forward — from monitoring, to kidney-preserving surgery, to complex systemic therapy decisions — and the right path depends heavily on details (subtype, grade, exact stage) that are easy to lose track of while processing a new diagnosis.

We help connect you with urologic oncology teams experienced in kidney-preserving surgical approaches and current immunotherapy/targeted therapy protocols, coordinate imaging and pathology review before you travel, and build a treatment estimate that honestly separates one-time surgical costs from the ongoing drug therapy costs that matter for advanced disease.

Reach out on WhatsApp or submit a quick inquiry — our team responds within 24 hours, with no obligation to proceed.

Frequently Asked Questions